C12N 2810/60
From viruses
Official title: from viruses
C12N2810/60 (From viruses) appears on 466 US grants and 698 published applications in this corpus.
Search patents in C12N- Granted patents
- 466
- Published applications
- 698
- Assignees
- 330
- Inventors
- 1,088
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 3 | 0 |
| 1997 | 3 | 0 |
| 1998 | 7 | 0 |
| 1999 | 14 | 0 |
| 2000 | 13 | 0 |
| 2001 | 16 | 5 |
| 2002 | 16 | 31 |
| 2003 | 11 | 43 |
| 2004 | 15 | 34 |
| 2005 | 9 | 36 |
| 2006 | 11 | 33 |
| 2007 | 19 | 23 |
| 2008 | 11 | 26 |
| 2009 | 11 | 21 |
| 2010 | 11 | 40 |
| 2011 | 8 | 18 |
| 2012 | 20 | 26 |
| 2013 | 12 | 30 |
| 2014 | 24 | 26 |
| 2015 | 22 | 42 |
| 2016 | 18 | 31 |
| 2017 | 38 | 36 |
| 2018 | 28 | 43 |
| 2019 | 25 | 36 |
| 2020 | 25 | 25 |
| 2021 | 16 | 30 |
| 2022 | 9 | 17 |
| 2023 | 19 | 11 |
| 2024 | 14 | 20 |
| 2025 | 12 | 7 |
| 2026 | 3 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2810/6072Negative strand rna virusesIndexing code144
- C12N 2810/6009Dsdna virusesIndexing code99
- C12N 2810/6027Ssdna virusesIndexing code77
- C12N 2810/6045Rna rev transcr virusesIndexing code70
- C12N 2810/609Positive strand rna virusesIndexing code51
- C12N 2810/6036Dna rev transcr virusesIndexing code2
- C12N 2810/6063Ds rna virusesIndexing code0
Recent patents
- Methods of delivering anionic agents in vivo using non-viral nanoparticle-based delivery systems16 Jun 2026US 12,653,905 B2Nanora Pharma Inc.
- Capsid-modified, rAAV3 vector compositions and methods of use in gene therapy of human liver cancer10 Mar 2026US 12,570,699 B2University of Florida Research Foundation, Inc.
- Oncolytic tumor viruses and methods of use6 Jan 2026US 12,514,887 B2The Salk Institute for Biological Studies
- Use of microvesicles in the treatment of medical conditions16 Dec 2025US 12,497,631 B2The General Hospital Corporation
- Method for improving retroviral transduction and gene editing in hematopoietic stem cells using clyclosporin H and UM1712 Dec 2025US 12,485,187 B2Fondazione Telethon
- Methods and Systems for Rapid Engineering of Resting Cells13 Aug 2026US 2026/0234558 A1Cellfe, Inc.
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- Targeting vector, preparation method therefor and use thereof21 May 2026US 2026/0137811 A1Shenzhen Genocury Biotech Co., Ltd.
- Engineered muscle targeting compositions7 May 2026US 2026/0125706 A1Massachusetts Institute of Technology
- Sarna delivery system, preparation method therefor and use thereof23 Apr 2026US 2026/0110000 A1Zhejiang Free Trade Zone Hongan Base Biotechnology Co., Ltd.
Most cited
By later US patents
- Virus vectors and methods of making and administering the same197US 7,172,893 B2The University of North Carolina at Chapel Hill · 2007
- Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes185US 5,316,931 ABiosource Genetics Corporation · 1994
- Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus184US 5,994,106 AGenVec, Inc. · 1999
- Recombinant parvovirus vectors and method of making167US 6,491,907 B1The University of North Carolina at Chapel Hill · 2002
- Targeting adenovirus with use of constrained peptide motifs158US 5,846,782 AGenVec, Inc. · 1998